[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07347379":3,"trial-entities:NCT07347379":69,"trial-summary:NCT07347379":74},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":21,"primary_purpose":16,"phases":22,"enrollment_info":23,"interventions":26,"primary_outcomes":37,"secondary_outcomes":43,"sex":44,"minimum_age":16,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":45,"std_ages":51,"locations":55,"central_contacts":65,"overall_officials":66,"references":67,"see_also_links":68},"NCT07347379","CSP-1003","Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study","ENROLLING_BY_INVITATION","2026-09","2026-01","2026-01-16","2025-11-13","RxSight, Inc.","INDUSTRY",false,"This is an observational, follow up study of subjects previously enrolled in the \"RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study\". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL and Control IOL in subjects previously implanted in the \"RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study\".",null,[18],"Aphakia Cataract",[20],"Light Adjustable Lens LAL Intraocular lens","OBSERVATIONAL",[],{"count":24,"type":25},500,"ESTIMATED",[27,33],{"type":28,"name":29,"description":30,"armGroupLabels":31},"DEVICE","Light Adjustable lens (LAL) and Light Delivery Device (LDD)","Experimental treatment group received Light adjustable lens with Light delivery Device treatments",[32],"Light adjustable lens (LAL) and Light Delivery Device (LDD)",{"type":28,"name":34,"description":35,"armGroupLabels":36},"Control IOL","Control treatment group received a Control IOL",[34],[38,41],{"measure":39,"timeFrame":40},"Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit compared between the RxSight LAL and Control group","Up to 55 months",{"measure":42,"timeFrame":40},"Mean manifest cylinder at the Long-Term follow up visit compared between the RxSight LAL and Control group",[],"ALL",{"inclusion":46,"exclusion":48,"raw_text":50},[47],"Subject and study eye with prior participation in the CSP-029 study.",[49],"Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.","Inclusion Criteria:\n\n* Subject and study eye with prior participation in the CSP-029 study.\n\nExclusion Criteria:\n\n* Subjects with serious co-morbid conditions that in the judgment of the investigator makes inclusion in the study not in the best interest of the subject.",[52,53,54],"CHILD","ADULT","OLDER_ADULT",[56],{"facility":57,"city":58,"state":59,"zip":60,"country":61,"geoPoint":62},"Focal Point Vision","San Antonio","Texas","78229","United States",{"lat":63,"lon":64},29.42412,-98.49363,[],[],[],[],{"nct_id":4,"conditions":70,"biomarkers":73},[71,72],"Aphakia","Cataract",[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]